Antibiotherapy - Page 5 de 7

info-atbvac > International News > Antibiotherapy

No benefit associated with moxifloxacin use for the treatment of recurrent drug-sensitive tuberculosis. ( Perumal R. et al. )

A Moxifloxacin-based Regimen for the Treatment of Recurrent, Drug-sensitive Pulmonary Tuberculosis: An Open-label, Randomized, Controlled Trial.

23 jan | Pr Pierre Tattevin

Although moxifloxacin is one of the most in vitro and in vivo active anti-tuberculosis (TB) drug, large randomized trials showed … Suite

Durations of Staphylococcus aureus bacteremia according to resistance to methicillin, and to the primary foci of infection. ( Kang CK, et al. )

Durations of Staphylococcus aureus bacteremia according to different phenotypes and a new concept of persistent bacteremia: a prospective cohort study

22 jan | Dr Jean-Pierre Bru

Little is known about the typical S. aureus bacteremias (SAB) duration following the administration of an effective antibiotic. Defining “persistence” … Suite

Continuous infusion of cefotaxime lead to better PK target attainment versus intermittent infusion in critically ill patients. ( Aardema H. and al. )

Continuous versus intermittent infusion of cefotaxime in critically ill patients: a randomized controlled trial comparing plasma concentrations.

16 jan | Dr Jean-Pierre Bru

To date, only two observational studies on cefotaxime dosing in critical care populations are available, none of them compared continuous … Suite

Is the subcutaneous route an alternative for administering ertapenem to older patients? ( Roubaud Baudron C. and al. )

Is the subcutaneous route an alternative for administering ertapenem to older patients? PHACINERTA study

14 jan | Dr Jean-Pierre Bru

Antibiotic administration by subcutaneous (SC) injection is a common practice in France, particularly in geriatric wards, as an alternative to … Suite

Short or Long Durations of Therapy for Common Inpatient Infections Associated with Bacteremia? ( Hojat LS. et al. )

Effectiveness of Shorter Versus Longer Durations of Therapy for Common Inpatient Infections Associated with Bacteremia: A Multicenter, Propensity-Weighted Cohort Study.

09 jan | Dr Jean-Pierre Bru

No or few national guidelines for pneumonia (PNA), urinary tract infection (UTI), and acute bacterial skin and skin structure infection … Suite

Dose addition of intravenous metronidazole to oral vancomycin improve outcomes in Clostridioides difficile infection? ( Wang Y. et al. )

Dose addition of intravenous metronidazole to oral vancomycin improve outcomes in Clostridioides difficile infection?

07 jan | Dr Jean-Pierre Bru

Dual therapy with vancomycin (oral/nasogastric tube/rectal instillation) and intravenous (IV) metronidazole is recommended only for the treatment of severe CDI … Suite

Lefamulin versus moxifloxacin for the treatment of community-acquired bacterial pneumonia. Results of a phase III trial. ( File TM. et al. )

Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.

19 déc | Dr Jean-Pierre Bru

Lefamulin is a pleuromutilin antibiotic. Its name comes from the pleuromutilin-producing fungus Pleurotus mutilus. Previous pleuromutilin are already used : … Suite

Can bacteremia due to glycopeptide-susceptible Enterococcus faecium be treated with linezolid? ( Echeverria-Esnal D. et al. )

Linezolid versus glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteremia: A propensity-score matched comparative study.

17 déc | Dr Philippe Lesprit

Vancomycin is the first-line treatment of glycopeptide (GP)-susceptible E. faecium (GSEF)-bloodstream infections (BSI) except for the rare amoxicillin-sensitive strains. GP … Suite

Does Colistin-Meropenem combination therapy reduce the emergence of colistin resistance vs. Colistin monotherapy? ( Dickstein Y. et al. & AIDA study group. )

Colistin Resistance Development Following Colistin-Meropenem Combination Therapy vs. Colistin Monotherapy in Patients with Infections Caused by Carbapenem-Resistant Organisms.

10 déc | Dr Jean-Pierre Bru

Colistin is one of a limited number of options for the treatment of carbapenem-resistant Gram-negative bacteria. A previously published randomized … Suite

In patients with sepsis every delay in antimicrobial administration after the initial clinician order is detrimental. ( Kashiouris MG. et al. )

Supply Chain Delays in Antimicrobial Administration After the Initial Clinician Order and Mortality in Patients With Sepsis.

05 déc | Dr Olivier Leroy

There is mounting evidence that delays in appropriate antimicrobial administration are responsible for preventable deaths in patients with sepsis. The … Suite